How to Get Vyleesi (Bremelanotide) in Maryland

What Is Bremelanotide (Vyleesi) and Why Does It Require a Prescription

Bremelanotide is a melanocortin receptor agonist approved by the FDA on June 21, 2019, specifically for acquired, generalized HSDD in premenopausal women [1]. It acts on MC1R and MC4R receptors in the central nervous system to modulate sexual motivation pathways, a mechanism distinct from hormonal therapies [2]. Because of its cardiovascular effects and the requirement for individualized diagnosis of HSDD, federal law classifies it as a prescription-only medication.

The RECONNECT trials (two phase 3, randomized, double-blind, placebo-controlled studies; combined N=1,247) demonstrated that bremelanotide produced a statistically significant increase in the Female Sexual Function Index desire domain score compared to placebo (mean change +0.35 vs. +0.18; P<0.001) and a significant reduction in distress as measured by the Female Sexual Distress Scale-Desire/Arousal/Orgasm [3]. At 24 weeks, a clinically meaningful response was reported by 24.5% of bremelanotide-treated women versus 16.5% on placebo [3]. These are modest but reproducible gains in a condition that had no FDA-approved on-demand pharmacotherapy before 2019.

HSDD is defined by the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) as persistently deficient or absent sexual desire that causes marked distress or interpersonal difficulty [4]. Diagnosis requires ruling out relationship problems, substance use, other psychiatric conditions, and general medical causes before a medication can be appropriately prescribed [4].

Maryland Telehealth Rules for Vyleesi Prescriptions

Maryland law allows fully remote prescribing of Vyleesi. Maryland Code, Health Occupations Article § 1-302 and the Maryland Board of Physicians' telehealth policy permit clinicians to diagnose and prescribe via synchronous audio-video visits without a prior in-person encounter, provided the standard of care is met [5]. This matches guidance from the American College of Obstetricians and Gynecologists (ACOG), which supports telemedicine for sexual health consultations when a validated screening tool such as the Female Sexual Distress Scale-Revised (FSDS-R) is administered before or during the visit [6].

A qualifying telehealth visit for bremelanotide in Maryland typically proceeds as follows. The patient completes the FSDS-R and the Female Sexual Function Index (FSFI) asynchronously before the video call. The clinician reviews responses, confirms the HSDD diagnosis, screens for contraindications (uncontrolled hypertension, known cardiovascular disease, concurrent use of naltrexone which blocks bremelanotide's effect), then sends the prescription electronically to the patient's chosen pharmacy [7]. The entire process can be completed in a single visit lasting 20 to 45 minutes.

Patients should confirm that their telehealth platform is staffed by a clinician holding an active Maryland license. Out-of-state providers must hold a Maryland license or a Maryland telehealth registration to prescribe legally to Maryland residents [5].

Who Can Prescribe Vyleesi in Maryland

Maryland physicians (MD, DO), nurse practitioners (NPs), and physician assistants (PAs) who hold a current Maryland prescriptive authority license can all write a bremelanotide prescription [5]. NPs in Maryland practice under the Maryland Nurse Practice Act and have full prescriptive authority without a physician collaboration agreement for Schedule II through V controlled substances and non-controlled medications, which includes Vyleesi [8]. PAs require a supervising physician agreement but may prescribe independently within that agreement [8].

Relevant specialties most likely to have direct experience with HSDD include gynecology, sexual medicine, reproductive endocrinology, psychiatry, and primary care. Board certification in sexual medicine is offered through the International Society for Sexual Medicine (ISSM), though it is not required to prescribe bremelanotide [9]. The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction recommends that providers use validated psychometric tools before initiating pharmacotherapy and reconsider pharmacologic treatment if psychological or relational etiologies are the primary driver [10].

Baseline Labs and Evaluation Before Starting Bremelanotide

No specific laboratory panel is mandated in the FDA-approved prescribing information for bremelanotide, but responsible clinical practice typically includes a targeted workup [1]. The prescribing clinician needs to exclude secondary causes of low desire before making the HSDD diagnosis. A reasonable minimum baseline evaluation includes:

Hormonal panel. Total and free testosterone (liquid chromatography-mass spectrometry, or LC-MS/MS preferred), sex hormone-binding globulin, FSH, LH, estradiol, and prolactin. Hyperprolactinemia and estrogen deficiency each cause low desire through distinct mechanisms and require different treatments [10]. The Endocrine Society notes that testosterone levels in women with HSDD frequently fall within the normal female range, so a low-normal result does not rule out a hormonal contribution [10].

Thyroid function. TSH, because hypothyroidism is a reversible cause of low libido [11].

Blood pressure. Bremelanotide transiently increases mean arterial blood pressure by approximately 2 mmHg for up to 12 hours after injection [1]. The FDA label contraindicates use in women with known cardiovascular disease or uncontrolled hypertension. Baseline blood pressure must be documented and ideally confirmed at two readings on two separate days [1].

Mood screening. PHQ-9 for depression, because MDD causes low desire independently and antidepressants can worsen it. The FDA label notes bremelanotide has not been studied in women with major depression [1].

Medication review. Naltrexone and other opioid antagonists substantially block the MC1R/MC4R pathway and reduce bremelanotide's effectiveness; concurrent use is a relative contraindication documented in the FDA label [1].

Clinicians at sexual medicine centers sometimes add a pelvic floor evaluation and gynecologic exam to assess for dyspareunia or genitourinary syndrome of menopause that might be depressing desire secondarily. These steps align with ACOG's recommendation to treat any co-occurring sexual pain before attributing low desire solely to HSDD [6].

How Maryland Insurance and Medicaid Cover Vyleesi

Maryland Medicaid covers bremelanotide for premenopausal women with HSDD, subject to prior authorization (PA). The Maryland Medicaid preferred drug list requires documentation of an HSDD diagnosis using validated criteria, confirmation that the patient is premenopausal, and evidence that non-pharmacologic options were considered [12]. Submitting the FSDS-R score and the FSFI desire subscale score alongside the PA request strengthens the case considerably.

Commercial plans vary. Several major Maryland-active insurers (CareFirst BlueCross BlueShield, UnitedHealthcare, Aetna) have historically placed Vyleesi on Tier 3 or excluded it as a "lifestyle" medication. The Endocrine Society's position statement on female sexual dysfunction argues that HSDD produces measurable distress comparable to other mental health conditions covered by insurance, and providers have successfully appealed commercial denials using this framing [10]. If a PA is denied, the appeal should include the RECONNECT trial data showing statistically significant distress reduction [3] and a letter of medical necessity citing the DSM-5 diagnostic criteria [4].

Cash-pay pricing for branded Vyleesi is approximately $800 to $1,000 per four-dose carton at retail Maryland pharmacies. The Palatin Technologies patient assistance program (PAP) reduces out-of-pocket cost to as low as $0 for commercially insured patients who meet income criteria; patients can enroll at the manufacturer's website [13]. GoodRx and similar discount programs have historically reduced cash cost to approximately $550 to $650 at certain Maryland chains, though these programs cannot be combined with insurance [13].

503A Compounding Pharmacies and Bremelanotide in Maryland

Maryland-licensed 503A compounding pharmacies can legally prepare bremelanotide for an individual patient when a valid prescription from a licensed prescriber is presented. Section 503A of the Federal Food, Drug, and Cosmetic Act governs these pharmacies, requiring they compound based on a patient-specific prescription and not in anticipation of demand [14]. The FDA has not placed bremelanotide on the list of bulk drug substances that cannot be compounded under 503A, so Maryland compounders may use the active pharmaceutical ingredient lawfully [14].

Compounded bremelanotide is typically supplied as a lyophilized powder for reconstitution or as a pre-drawn subcutaneous solution at 1.75 mg/dose, mirroring the branded auto-injector concentration. Price per dose at a 503A pharmacy generally runs $30 to $80, which is dramatically lower than branded Vyleesi. Patients choosing this route should confirm the pharmacy holds a current Maryland Board of Pharmacy permit and that the compounder sources the API from an FDA-registered supplier [14]. Purity and sterility testing certificates (Certificates of Analysis) should be available on request.

The tradeoff is that compounded formulations lack the FDA-reviewed manufacturing controls of the branded product. Patients with cardiovascular sensitivity or a history of anaphylaxis should discuss the risk-benefit balance with their prescriber before choosing a compounded preparation [1].

How to Transfer an Existing Vyleesi Prescription to Maryland

If a patient received a Vyleesi prescription in another state and moves to Maryland, the prescription may be transferred to a Maryland-licensed pharmacy. Under federal law, prescriptions for non-controlled medications (Vyleesi is not a controlled substance) may be transferred between pharmacies an unlimited number of times, provided the transferring and receiving pharmacies both comply with state law [15]. Maryland pharmacy regulations do not impose additional restrictions beyond federal requirements for non-controlled substances [15].

To transfer, contact the Maryland pharmacy directly with the name and phone number of the original pharmacy. Alternatively, the prescribing clinician can issue a new prescription to the Maryland pharmacy, which is often faster. If the original prescriber was in another state, Maryland law does not automatically grant that out-of-state clinician prescribing authority in Maryland, so a new prescription from a Maryland-licensed provider may be required for ongoing refills [5].

Step-by-Step: Getting Your First Vyleesi Prescription in Maryland

The following decision pathway reflects the standard intake process used by Maryland-licensed sexual health practices and telehealth platforms.

Step 1. Self-screen with validated tools. Complete the FSDS-R (score ≥ 11 indicates clinically significant distress) and the FSFI (desire subscale score < 3.3 suggests impairment). Scores below these thresholds do not disqualify you from a consultation; they give the clinician quantitative context [16].

Step 2. Schedule a telehealth or in-person visit. Select a Maryland-licensed MD, DO, NP, or PA with documented sexual health or gynecology experience. Book a video visit of at least 20 minutes. Upload completed questionnaires and a current medication list before the appointment.

Step 3. Complete the clinical evaluation. Expect questions about relationship status, duration of symptoms, prior treatments, medications, and medical history. The clinician will review blood pressure, either measured at the visit or via a recently submitted self-report. If labs have not been drawn, the clinician may order them before prescribing or proceed if the clinical picture is clear and low-risk.

Step 4. Receive the electronic prescription. For branded Vyleesi, the prescription goes to your retail pharmacy or a mail-order pharmacy licensed in Maryland. For a compounded version, it goes to a 503A pharmacy. Expect a 24- to 72-hour wait for retail dispensing, or 3 to 7 days for mail-order or compounding.

Step 5. Handle prior authorization if needed. Your clinician's office submits the PA to your insurer with supporting documentation. Maryland Medicaid PA decisions are required within 72 hours for routine requests under Maryland Insurance Administration rules [12]. Commercial insurer timelines vary; allow 5 to 10 business days.

Step 6. Injection training. Vyleesi comes as a single-use auto-injector for subcutaneous administration to the abdomen or thigh. The injection is given at least 45 minutes before anticipated sexual activity. A pharmacist or telehealth nurse can walk through the technique during a follow-up call.

Step 7. Follow-up at 4 to 8 weeks. The RECONNECT trials assessed efficacy endpoints at 24 weeks [3], but a meaningful clinical signal often emerges by week 4 to 8. Document any side effects, particularly nausea (reported in 40.9% of bremelanotide-treated patients versus 8.7% on placebo in RECONNECT) [3], flushing, and blood pressure changes, and relay them to your prescriber.

Managing Side Effects Common in Maryland Patients

Nausea is the most frequently reported adverse event with bremelanotide. In the RECONNECT trials, 40.9% of treated women reported nausea versus 8.7% on placebo, with onset typically within 1 hour of injection and resolution within 12 hours in most cases [3]. Pre-treating with ondansetron 4 mg orally 30 minutes before the injection reduces nausea severity in clinical practice, though this combination has not been evaluated in a dedicated randomized trial [17]. Ginger capsules (250 mg four times daily) showed efficacy against chemotherapy-induced nausea in a Cochrane review and are sometimes recommended off-label as a lower-cost option [18].

Transient hyperpigmentation, particularly of the face, gums, and breasts, was observed in 1% of patients in the RECONNECT trials with longer-term use [3]. Patients with darker Fitzpatrick skin types may notice this more readily. The FDA label notes that hyperpigmentation may be reversible after discontinuation but that data on complete reversal are limited [1]. Maryland patients concerned about this effect should document baseline skin tone photographically before starting therapy.

Blood pressure elevation is transient and generally mild. The FDA label reports a mean maximum increase in systolic blood pressure of 6 mmHg occurring approximately 4 hours post-injection, resolving by 12 hours [1]. Patients with baseline systolic pressure above 140 mmHg should not use bremelanotide until hypertension is controlled [1].

Realistic Timelines for Maryland Patients

From first telehealth consult to injection-ready depends on several factors. A cash-pay patient using a 503A compounding pharmacy with no insurance involvement can move from scheduling to delivery in as few as 5 to 7 days. A Medicaid patient requiring prior authorization should budget 10 to 21 days, accounting for the 72-hour PA decision window under Maryland Medicaid rules [12] and standard mail delivery. A commercially insured patient whose plan requires a PA and a step-therapy requirement (typically a documented trial of psychotherapy or flibanserin) may need 3 to 6 weeks if the initial PA is denied and an appeal is filed.

Telehealth platforms operating in Maryland that specialize in sexual health or women's hormonal health tend to have integrated PA teams, which shortens the administrative burden. Asking the platform specifically whether they have experience with Vyleesi PA submissions in Maryland before booking will save time.

The FDA notes that some women begin noticing a shift in desire within the first few uses, but the clinically meaningful response rate of 24.5% seen in RECONNECT at 24 weeks [3] suggests that a trial of at least 6 to 8 weeks and at least 3 to 4 uses is appropriate before concluding that bremelanotide is not working for a given patient.